GO:0018423 protein C-terminal leucine carboxyl O-methyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0018423 describes the enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to the free alpha-carboxyl group of a C-terminal leucine residue, forming a leucine methyl ester.
• The best-characterized enzyme carrying this activity is leucine carboxyl methyltransferase 1 (LCMT-1), which methylates protein phosphatase 2A (PP2A) and related phosphatases PP4 and PP6.
• This methylation is reversible and regulates the assembly of PP2A holoenzymes by controlling the association of regulatory B subunits.
• Loss of LCMT-1 activity leads to accumulation of demethylated PP2A, which is associated with inactive phosphatase populations and can be reactivated by the phosphotyrosyl phosphatase activator.
• The reaction is highly specific for leucine at the protein C-terminus and represents a novel eukaryotic protein carboxyl methylation reaction distinct from other methyltransferases.
• Dysregulation of this activity has been linked to cancer, neurodegenerative diseases, and developmental disorders through its impact on phosphatase signaling.
Description
Protein C-terminal leucine carboxyl O-methyltransferase activity (GO:0018423) is a molecular function that catalyzes the methylation of the free alpha-carboxyl group of a C-terminal leucine residue, using S-adenosyl-L-methionine as the methyl donor. This modification was first described in bovine brain cytosolic 36-kDa polypeptides and represents a novel eukaryotic protein carboxyl methylation reaction. The enzyme responsible, leucine carboxyl methyltransferase 1 (LCMT-1), was subsequently purified from porcine brain and its human homologue cloned. This activity is critical for the regulation of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase that controls numerous cellular processes. By methylating the C-terminal leucine of the PP2A catalytic subunit, LCMT-1 promotes the assembly of specific PP2A holoenzymes, thereby influencing substrate specificity and cellular signaling. Researchers study this activity to understand how post-translational methylation modulates phosphatase function in health and disease, with implications for cancer, neurodegeneration, and metabolic disorders.
protein C-terminal leucine carboxyl O-methyltransferase activity At A Glance
| GO ID | GO:0018423 |
|---|---|
| GO term | protein C-terminal leucine carboxyl O-methyltransferase activity |
| Ontology | molecular_function |
| Synonym | protein-leucine O-methyltransferase activity; protein phosphatase methyltransferase activity |
| Major function | Methylation of C-terminal leucine residues, particularly on protein phosphatase 2A (PP2A) and related phosphatases |
| Reaction | S-adenosyl-L-methionine + [protein]-L-leucine = S-adenosyl-L-homocysteine + [protein]-L-leucine methyl ester |
| Substrate specificity | Requires a free alpha-carboxyl group of a C-terminal leucine residue |
| Cofactor | S-adenosyl-L-methionine (SAM) as methyl donor |
| Key enzyme | Leucine carboxyl methyltransferase 1 (LCMT-1) |
What Is GO:0018423?
This GO term describes an enzymatic activity that catalyzes the reaction: S-adenosyl-L-methionine + [protein]-L-leucine = S-adenosyl-L-homocysteine + [protein]-L-leucine methyl ester. The modification occurs exclusively at the oxygen atoms of the free alpha-carboxyl group of a leucine residue located at the C-terminus of a protein. This activity is also known as protein-leucine O-methyltransferase activity or protein phosphatase methyltransferase activity, reflecting its role in methylating protein phosphatases such as PP2A.
Why Is protein C-terminal leucine carboxyl O-methyltransferase activity Important in Cell Biology?
Protein C-terminal leucine carboxyl O-methyltransferase activity is essential for the proper function of protein phosphatase 2A (PP2A), a tumor suppressor and major regulator of cell signaling. This methylation event controls the assembly of PP2A holoenzymes by facilitating the binding of regulatory B subunits, thereby determining substrate specificity and phosphatase activity. Dysregulation of this activity has been implicated in cancer, neurodegenerative diseases, and developmental disorders, making it a potential therapeutic target. Understanding this molecular function provides insights into how post-translational modifications regulate phosphatase signaling and cellular homeostasis.
• Regulates PP2A holoenzyme assembly and substrate specificity.
• Controls the association of regulatory B subunits with the PP2A core enzyme.
• Influences cell cycle progression, apoptosis, and signal transduction through PP2A.
• Dysregulation is linked to cancer, including breast and lung cancers.
• Implicated in neurodegenerative diseases such as Alzheimer's disease.
• Plays a role in metabolic regulation and insulin signaling.
• Represents a potential target for therapeutic intervention in phosphatase-related disorders.
• Provides a model for studying reversible protein methylation in eukaryotes.
• Essential for embryonic development in model organisms.
• Modulates the activity of PP4 and PP6, expanding its regulatory scope.
What Happens During protein C-terminal leucine carboxyl O-methyltransferase activity?
Substrate Recognition and Binding
In simple terms: The enzyme finds and grabs onto the target protein's tail end.
The enzyme LCMT-1 specifically recognizes proteins with a C-terminal leucine residue, such as the catalytic subunit of PP2A. This recognition involves binding to the C-terminal tail of the substrate, positioning the free alpha-carboxyl group for methylation. The specificity for leucine at the C-terminus is a defining feature of this activity.
Methyl Group Transfer
In simple terms: The enzyme attaches a methyl group to the end of the protein.
Using S-adenosyl-L-methionine (SAM) as the methyl donor, the enzyme transfers a methyl group to the oxygen atom of the free alpha-carboxyl group of the C-terminal leucine, forming a leucine methyl ester and releasing S-adenosyl-L-homocysteine. This reaction is a carboxyl O-methylation, distinct from other types of protein methylation.
Conformational Change and Holoenzyme Assembly
In simple terms: The methyl mark helps the protein assemble into a functional complex.
Methylation of the PP2A catalytic subunit induces a conformational change that promotes the binding of regulatory B subunits, leading to the formation of specific PP2A holoenzymes. This methylation is required for the stable association of B subunits, thereby determining substrate specificity and cellular localization.
Reversibility and Regulation
In simple terms: The methyl mark can be removed to switch the protein's function off.
The methylation is reversible; a methylesterase can remove the methyl group, leading to the dissociation of B subunits and inactivation of PP2A. The balance between methylation and demethylation regulates PP2A activity and is controlled by cellular signals.
Key Genes Involved in GO:0018423 protein C-terminal leucine carboxyl O-methyltransferase activity
The following genes and proteins are directly involved in or regulated by protein C-terminal leucine carboxyl O-methyltransferase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LCMT1 | Leucine carboxyl methyltransferase 1; catalyzes methylation of PP2A, PP4, and PP6 | Central enzyme for GO:0018423; knockout studies show loss of PP2A methylation |
| PPP2CA | Catalytic subunit of PP2A; primary substrate for LCMT1 | Methylation regulates PP2A holoenzyme assembly and activity |
| PPP2CB | Catalytic subunit of PP2A; alternative substrate | Methylation status affects PP2A function in different tissues |
| PPP4C | Catalytic subunit of PP4; methylated by LCMT1 | LCMT1 methylates PP4 and regulates its holoenzyme formation |
| PPP6C | Catalytic subunit of PP6; methylated by LCMT1 | LCMT1 methylates PP6, affecting its function |
| PPME1 | Protein phosphatase methylesterase 1; removes methyl group from PP2A | Reverses methylation, regulating PP2A activity |
| PPP2R1A | A subunit of PP2A; scaffold for holoenzyme assembly | Methylation of C subunit affects A subunit interactions |
| PPP2R2A | B subunit of PP2A; binding is methylation-dependent | Methylation controls B subunit association |
| PPP2R5A | B' subunit of PP2A; binding is methylation-dependent | Methylation regulates B' subunit recruitment |
| PPP2R5C | B' subunit of PP2A; binding is methylation-dependent | Methylation affects B' subunit binding |
| PPP2R5D | B' subunit of PP2A; binding is methylation-dependent | Methylation influences B' subunit assembly |
| PPP2R3A | B'' subunit of PP2A; binding may be methylation-dependent | Methylation status impacts B'' subunit association |
| PTPA | Phosphotyrosyl phosphatase activator; reactivates demethylated PP2A | Reactivation of inactive PP2A population |
| LCMT2 | Leucine carboxyl methyltransferase 2; related enzyme | Potential role in methylating other substrates |
| SAM | S-adenosyl-L-methionine; methyl donor | Cofactor for the methylation reaction |
| SAH | S-adenosyl-L-homocysteine; byproduct | Product of the reaction |
| PP2A | Protein phosphatase 2A; major substrate | Key target for methylation |
How Is protein C-terminal leucine carboxyl O-methyltransferase activity Regulated?
The activity of protein C-terminal leucine carboxyl O-methyltransferase is regulated at multiple levels. The expression and activity of LCMT-1 can be modulated by cellular signals, and the methylation status of PP2A is dynamically controlled by the opposing action of the methylesterase PPME1. Additionally, the phosphotyrosyl phosphatase activator (PTPA) can reactivate demethylated PP2A, providing another layer of regulation. The balance between methylation and demethylation is critical for PP2A holoenzyme assembly and function, and disruptions in this balance are associated with disease.
protein C-terminal leucine carboxyl O-methyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LCMT1 | Cancer, neurodegenerative diseases | LCMT1 knockout cell lines and mouse models |
| PPP2CA | Cancer, developmental disorders | Point mutation knock-in of methylation site |
| PPP2R1A | Intellectual disability, developmental delay | Patient-derived iPSCs with mutations |
| PPP2R5D | Developmental disorders | Knock-in mouse models |
| PPME1 | Cancer, Alzheimer's disease | Overexpression and knockout models |
Cancer
Dysregulation of protein C-terminal leucine carboxyl O-methyltransferase activity has been implicated in cancer. LCMT-1 is downregulated in several cancer types, leading to reduced PP2A methylation and altered phosphatase activity, which can promote tumorigenesis. Loss of LCMT-1 function results in decreased PP2A holoenzyme formation, affecting signaling pathways that control cell proliferation and survival.
Neurodegenerative Diseases
In neurodegenerative diseases such as Alzheimer's disease, impaired PP2A methylation has been observed. The accumulation of demethylated PP2A is associated with tau hyperphosphorylation and neurofibrillary tangle formation, suggesting a role for LCMT-1 in disease pathogenesis. Reduced LCMT-1 activity may contribute to neuronal dysfunction by disrupting PP2A-mediated dephosphorylation of tau.
Developmental Disorders
Mutations in genes encoding PP2A subunits or LCMT-1 can cause developmental disorders. For example, mutations in PPP2R1A or PPP2R5D lead to intellectual disability and developmental delay, potentially through altered PP2A methylation and holoenzyme assembly. Understanding the role of LCMT-1 in these disorders may provide therapeutic insights.
From protein C-terminal leucine carboxyl O-methyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of LCMT1 knockout on PP2A methylation? | LCMT1 knockout cell lines (e.g., HEK293, HeLa) |
| How does loss of LCMT1 affect PP2A holoenzyme assembly? | Knockout cells followed by immunoprecipitation and western blot |
| What is the role of LCMT1 in cancer cell proliferation? | Cancer cell lines with LCMT1 overexpression or knockdown |
| How does methylation of PP2A affect B subunit binding? | Point mutation of the C-terminal leucine to alanine in PPP2CA |
| Can PTPA reactivate demethylated PP2A? | In vitro assays with purified PP2A and PTPA |
| What are the substrates of LCMT1 beyond PP2A? | Knock-in of tagged LCMT1 followed by mass spectrometry |
How to Study the protein C-terminal leucine carboxyl O-methyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro methyltransferase assay | Enzymatic activity of LCMT-1 | Kinetic studies and inhibitor screening |
| Western blot with methylation-specific antibodies | Methylation status of PP2A | Analysis of cell lysates and tissues |
| Immunoprecipitation | Interaction between PP2A and B subunits | Holoenzyme assembly studies |
| Mass spectrometry | Identification of methylated peptides | Global substrate profiling |
| CRISPR knockout | Loss of LCMT1 function | Phenotypic analysis in cells and mice |
| RNA interference | Knockdown of LCMT1 expression | Transient loss-of-function studies |
| Phosphatase activity assay | PP2A activity | Functional consequences of methylation |
| Site-directed mutagenesis | Effect of C-terminal leucine mutation | Mapping methylation site |
Biochemical Assays for Methyltransferase Activity
In vitro methyltransferase assays using recombinant LCMT-1 and substrate peptides or proteins can directly measure the transfer of methyl groups from S-adenosyl-L-methionine to the C-terminal leucine. These assays typically use radioactive SAM or fluorescent analogs and can be coupled with mass spectrometry to confirm the formation of leucine methyl esters.
Antibody-Based Detection of Methylated PP2A
Methylation-specific antibodies that recognize the methylated C-terminus of PP2A are widely used in western blotting and immunoprecipitation to assess the methylation status of PP2A in cells and tissues. These antibodies can also be used for immunohistochemistry to study the distribution of methylated PP2A in disease models.
Proteomics and Mass Spectrometry
Mass spectrometry-based proteomics can identify and quantify C-terminal leucine methylation on PP2A and other substrates. Enrichment of methylated peptides using methyl-specific antibodies or chemical probes followed by LC-MS/MS allows global profiling of LCMT-1 substrates. This approach can reveal novel substrates and methylation sites.
Genetic Knockout and Knockdown Models
CRISPR/Cas9-mediated knockout of LCMT1 or RNA interference knockdown can be used to study the loss of function of this activity. These models show reduced PP2A methylation and altered holoenzyme assembly, providing insights into the physiological roles of LCMT-1. Rescue experiments with wild-type or catalytically dead LCMT-1 can confirm specificity.
How CRISPR Can Be Used to Study GO:0018423 protein C-terminal leucine carboxyl O-methyltransferase activity
Knockout
CRISPR/Cas9-mediated knockout of LCMT1 generates cell lines and animal models that completely lack protein C-terminal leucine carboxyl O-methyltransferase activity. These models exhibit reduced PP2A methylation, impaired holoenzyme assembly, and altered cellular signaling, making them valuable for studying the physiological roles of this modification. Knockout of the methylation site in PPP2CA (e.g., L309A) can mimic the loss of methylation and disrupt B subunit binding.
Point Mutation
Point mutations can be introduced into the catalytic domain of LCMT1 to abolish its enzymatic activity while preserving protein structure, or into the C-terminal leucine of PP2A to prevent methylation. These models help distinguish between methylation-dependent and independent functions of LCMT-1 and PP2A. For example, mutation of the catalytic cysteine or the SAM-binding motif in LCMT1 can inactivate the enzyme.
Knock-in
Knock-in of tagged LCMT1 (e.g., FLAG, HA, or GFP) allows for affinity purification and localization studies. Knock-in of a methylation-deficient PP2A mutant (e.g., L309A) can be used to study the specific consequences of lost methylation in vivo. These models are essential for understanding the dynamic regulation of PP2A methylation.
Overexpression
Overexpression of wild-type LCMT1 or its catalytically inactive mutant can be achieved via lentiviral or plasmid transfection. Overexpression studies can reveal gain-of-function phenotypes, such as increased PP2A methylation and altered cell growth, and can be used to test the effects of LCMT1 on cancer cell proliferation. Inducible overexpression systems allow temporal control of LCMT1 levels.
How EDITGENE Supports protein C-terminal leucine carboxyl O-methyltransferase activity Research
Researchers studying protein C-terminal leucine carboxyl O-methyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in a specific phenotype, such as altered PP2A methylation or cancer cell growth. EDITGENE provides a comprehensive suite of CRISPR-based services to facilitate these investigations, from generating knockout cell lines to creating precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for protein C-terminal leucine carboxyl O-methyltransferase activity research.
Frequently Asked Questions About protein C-terminal leucine carboxyl O-methyltransferase activity
What is protein C-terminal leucine carboxyl O-methyltransferase activity?
It is an enzymatic activity that transfers a methyl group from S-adenosyl-L-methionine to the free alpha-carboxyl group of a C-terminal leucine residue on a protein, forming a leucine methyl ester.
What genes are involved in protein C-terminal leucine carboxyl O-methyltransferase activity?
The primary gene is LCMT1, which encodes leucine carboxyl methyltransferase 1. Its main substrates are PPP2CA, PPP2CB, PPP4C, and PPP6C, and the reverse reaction is catalyzed by PPME1.
What is the role of LCMT1 in PP2A methylation?
LCMT1 methylates the C-terminal leucine of the PP2A catalytic subunit, which promotes the assembly of PP2A holoenzymes by facilitating the binding of regulatory B subunits.
How does methylation affect PP2A function?
Methylation of PP2A is required for the stable association of B subunits, which determines substrate specificity and cellular localization. Demethylation leads to dissociation of B subunits and inactivation of PP2A.
What diseases are associated with defects in this activity?
Dysregulation of LCMT1 and PP2A methylation has been implicated in cancer, neurodegenerative diseases such as Alzheimer's disease, and developmental disorders.
How can I study protein C-terminal leucine carboxyl O-methyltransferase activity in the lab?
Common methods include in vitro methyltransferase assays, western blotting with methylation-specific antibodies, mass spectrometry, and CRISPR knockout models.
What is the reaction catalyzed by this enzyme?
The reaction is: S-adenosyl-L-methionine + [protein]-L-leucine = S-adenosyl-L-homocysteine + [protein]-L-leucine methyl ester.
Is this methylation reversible?
Yes, the methyl group can be removed by protein phosphatase methylesterase 1 (PPME1), making the modification dynamic and reversible.
What are the synonyms for this GO term?
The synonyms are protein-leucine O-methyltransferase activity and protein phosphatase methyltransferase activity.
Can CRISPR be used to study this activity?
Yes, CRISPR/Cas9 can generate knockout, point mutation, and knock-in models for LCMT1 and its substrates, enabling precise functional studies.
Conclusion
Protein C-terminal leucine carboxyl O-methyltransferase activity (GO:0018423) is a critical post-translational modification that regulates protein phosphatase 2A and related phosphatases. Through the action of LCMT-1, this methylation controls holoenzyme assembly, substrate specificity, and cellular signaling, with profound implications for cancer, neurodegeneration, and development. Continued research using advanced CRISPR models and biochemical assays will further elucidate the mechanistic details and therapeutic potential of this activity.
References
- 1. Hwang J et al.. 2016. Leucine Carboxyl Methyltransferase 1 (LCMT-1) Methylates Protein Phosphatase 4 (PP4) and Protein Phosphatase 6 (PP6) and Differentially Regulates the Stable Formation of Different PP4 Holoenzymes.. J Biol Chem 291(40):21008-21019 PMID: 27507813
- 2. Xie H et al.. 1993. Methyl esterification of C-terminal leucine residues in cytosolic 36-kDa polypeptides of bovine brain. A novel eucaryotic protein carboxyl methylation reaction.. J Biol Chem 268(18):13364-71 PMID: 8514774
- 3. De Baere I et al.. 1999. Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue.. Biochemistry 38(50):16539-47 PMID: 10600115
- 4. Longin S et al.. 2004. An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator.. Biochem J 380(Pt 1):111-9 PMID: 14748741
- 5. Tolstykh T et al.. 2000. Carboxyl methylation regulates phosphoprotein phosphatase 2A by controlling the association of regulatory B subunits.. EMBO J 19(21):5682-91 PMID: 11060019
